Trials / Completed
CompletedNCT05440136
A Safety Study of LY3462817 in Healthy Japanese and Non-Japanese Participants
A Single-Ascending Dose, Safety, Tolerability, and Pharmacokinetic Study of LY3462817 in Healthy Japanese and Non-Japanese Participants
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 33 (actual)
- Sponsor
- Eli Lilly and Company · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Accepted
Summary
The main purpose of this study is to evaluate the safety and tolerability of LY3462817 in healthy Japanese and non-Japanese participants. The study will also assess how fast LY3462817 gets into the blood stream and how long it takes the body to remove it. The study is open to healthy participants. The study will last up to approximately 12 weeks.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | LY3462817 (SC) | Administered SC. |
| DRUG | Placebo (SC) | Administered SC. |
| DRUG | LY3462817 (IV) | Administered IV. |
| DRUG | Placebo (IV) | Administered IV. |
Timeline
- Start date
- 2022-06-28
- Primary completion
- 2023-03-08
- Completion
- 2023-03-08
- First posted
- 2022-06-30
- Last updated
- 2023-03-30
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05440136. Inclusion in this directory is not an endorsement.